title: Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?
authors.forename: Ann V
authors.initials: AV
authors.lastname: Schwartz
authors.forename: Deborah E
authors.initials: DE
authors.lastname: Sellmeyer
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D050723:Fractures, Bone; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C089946:2,4-thiazolidinedione